Japan Sees New OTC Drug Law Spurring ‘Switch’ Production
This article was originally published in PharmAsia News
The effort by Japan's Ministry of Health to encourage more production of over-the-counter "switch drugs" appears to be bearing fruit. Drug makers are racing to release their versions of the drugs and help revive the OTC market in Japan. New laws take effect next June that classify OTC drugs into three groups based on their efficacy and risk of side effects. The "switch drugs" would require a pharmacist to explain how the drugs for lifestyle ailments are to be used. That provision is expected to eliminate pharmacy competition by most discount retailers, so manufacturers are focusing first on that sector of medicines. (Click here for more - a subscription may be required
You may also be interested in...
TOKYO - Japan's self-medication drug industry, responding to MHLW's new policies to encourage over-the-counter drug use, is stepping up efforts to launch over-the-counter pharmaceuticals by unveiling 20 additional chemical composites
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.